CTOs on the Move


 
Lupin is a USD 2.55 billion innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.lupin.com
  • Harborplace Tower 111 South Calvert Street 21st Floor
    Baltimore, MD USA 21202
  • Phone: 410.576.2000

Executives

Name Title Contact Details
Marc Bowman
Associate Director of Information Technology Profile

Similar Companies

Md's Choice Inc

Md's Choice Inc is a Louisville, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Caraco Pharmaceutical Laboratories

Caraco Pharmaceutical Laboratories, Ltd. (Caraco) is engaged in the business of developing, manufacturing, marketing and distributing generic and private-label pharmaceuticals to wholesalers, distributors, warehousing and non-warehousing chain drugstores

AMGIT

AMGIT is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Child & Family Services

Child & Family Services is a private, nonprofit, human service agency that provides adoption services, mental health counseling, psychiatry and specialized support programs to people of all ages living in southeastern Massachusetts.

TransCode Therapeutics

TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company`s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. The Company`s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing diagnostic products related to its planned therapeutics business.